Sandoz is moving quickly to operationalize its newly announced Bio100 strategy with a major capital commitment. The pharmaceutical company said it will invest approximately USD 300 million in a new production facility for biosimilar active pharmaceutical ingredients in Ljubljana, Slovenia.
The plant is scheduled to begin operations in 2029 and will expand Sandoz's European production and supply chain for biosimilar products.
The investment announcement came hours after Sandoz unveiled the Bio100 initiative, signaling that the company is backing its strategic roadmap with immediate, tangible spending rather than delaying execution.
Sandoz, which was spun off from Novartis, has been pursuing growth through its biosimilar franchise. The Bio100 strategy represents a key pillar of that effort, focusing on expanding the pipeline and manufacturing footprint for biosimilar medicines across key therapeutic areas.
The Ljubljana site will add to Sandoz's existing European manufacturing network, strengthening the company's ability to produce complex biosimilar molecules at scale and serve growing demand in the region.
